tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 385 are a BUY (86.52%), 58 are a HOLD (13.03%), 2 are a SELL (0.45%).
Analyst Robyn Karnauskas, currently employed at TRUIST, carries an average stock price target met ratio of 57.2% that have a potential upside of 37.79% achieved within 419 days.
Robyn Karnauskas’s has documented 880 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Technology, Energy sectors.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 08-Jul-2026.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for FATE (FATE THERAPEUTICS) at 1/5/2023. The price target of $7 was fulfilled within 1 day with a profit of $4 (36.36%) receiving and performance score of 363.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 18-Nov-2020
$282
$22.64 (8.73%)
$273
4 days ago
(22-Jul-2026)
14/17 (82.35%)
$28.7 (11.33%)
409
Hold Since 15-Jul-2026
$260
$0.64 (0.25%)
$276
11 days ago
(15-Jul-2026)
19/21 (90.48%)
$15.89 (6.51%)
284
Hold Since 07-Jan-2026
$260
$0.64 (0.25%)
$230
13 days ago
(13-Jul-2026)
2/3 (66.67%)
$12 (4.84%)
89
Buy Since 05-Feb-2024
$300
$40.64 (15.67%)
$258
13 days ago
(13-Jul-2026)
16/17 (94.12%)
$52 (20.97%)
318
Buy Since 25-Feb-2026
$280
$20.64 (7.96%)
$260
16 days ago
(10-Jul-2026)
6/7 (85.71%)
$31.92 (12.87%)
161
Which stock is Robyn Karnauskas is most bullish on?
What Year was the first public recommendation made by Robyn Karnauskas?
